MENU

Telix Pharmaceuticals Ltd establishes presence in Japan

Telix Pharmaceuticals Ltd (ASX: TLX) is a biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation. The company is developing a portfolio of oncology products that address medical needs for renal, prostate and brain cancer.

Today, the company has announced the establishment of Telix Pharmaceuticals (Japan) Ltd and appointed the first two members of the Japanese team.

The aim of the Japanese company is to support Japanese clinical and radiopharmaceutical manufacturing activities and establish a commercial footprint in Japan.

Telix Co-Founder and CEO Dr. Christian Behrenbruch stated “Japan is one of the most prospective markets for Telix’s products and our activities in Japan covers are range of manufacturing and collaboration activities with leading Japanese sites and biopharmaceutical companies.”

“The Japanese radiopharmaceutical landscape is evolving rapidly and we are pleased to have been able to hire two extremely high-caliber executives to lead our development and commercial activity.”

Don't Buy A SINGLE Stock Until You Read This

While conflict overseas is all media talking-heads seem to mention these days, the billionaire founder of Tesla is losing sleep over what he sees as a far bigger threat.

Elon Musk Warns: This has "vastly more risk than North Korea"

If you missed your opportunity to get in on Google, Microsoft, or Amazon in their early days, don't let it happen again. This emerging technology trend could offer a second chance for anyone who wishes they took part in these millionaire-maker stocks.

Click here to discover more!

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.